ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Innovation, Partnerships Driving Nationwide Interoperability to Address Healthcare’s Top Challenges

More than 2 million providers exchanged patient data more than 21 billion times in 2022, tipping the scale for interoperability and better-informed patient care

Key Insights

  1. Greater interoperability is keeping care teams better informed and connected.
  2. Clinicians are tackling medication cost concerns before they hinder adherence.
  3. The specialty medication journey is becoming less painful.
  4. Healthcare professionals are accessing information that’s richer and more complete.
  5. Care teams are evolving and tapping into existing technologies.

More than 2 million care providers exchanged patient clinical and benefit information more than 21.7 billion times in 2022, reaching virtually every American patient, according to the Surescripts 2022 National Progress Report. In the face of ongoing provider burnout, staffing shortages, and increasing costs, interoperability in healthcare flourished, and the Surescripts Network Alliance came together to simplify how health intelligence is shared.

“While there is no single solution to the challenges facing healthcare today, we have billions of reasons for hope that come with every exchange of secure patient information,” said Frank Harvey, Chief Executive Officer of Surescripts. “I’m inspired every day when I see the ways the Surescripts Network Alliance is coming together to solve healthcare’s shared challenges with shared health intelligence—and making significant headway toward better, safer, less costly care in America.”

Report highlights:

As the nation’s leading health information network, Surescripts exchanged much more than electronic prescriptions in 2022, including patient eligibility and formulary data that informed 4.34 billion care events, nearly 500 million prescription benefit checks at the point of prescribing, and 44% more prior authorizations processed electronically compared to 2021. At the same time, the number of prescribers using the Surescripts network increased by nearly 8%, and that growth was largely attributed to new prescriber specialties and roles across evolving care teams—including residents, nurse practitioners, dentists and physician assistants.

“It’s clear that the interoperability that’s happening across the Surescripts network is having a direct impact on patients’ lives,” explained Alan Swenson, Executive Director of Carequality. “Thousands of individual healthcare organizations across the country are innovating to make life easier and safer for their staff and patients.”

Download the Surescripts 2022 National Progress Report to learn more.

About Surescripts

Our purpose is to serve the nation through simpler, trusted health intelligence sharing, in order to increase patient safety, lower costs and ensure quality care. At Surescripts, we align healthcare organizations across the nation and give healthcare professionals the trusted insights they need to serve patients. We convene the Surescripts Network Alliance® to enhance prescribing, better inform care decisions and advance healthcare as a whole. Visit us at surescripts.com and follow us at twitter.com/Surescripts.

NEW DATA: Surescripts 2022 National Progress Report: 2+M care providers exchanged patient clinical & benefit information 21.7B times, reaching virtually every American patient - simplifying how health intelligence is shared. #healthIT #interoperability

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.16
-0.51 (-0.22%)
AAPL  277.55
+0.58 (0.21%)
AMD  214.24
+8.11 (3.93%)
BAC  52.99
+0.51 (0.97%)
GOOG  320.28
-3.36 (-1.04%)
META  633.61
-2.61 (-0.41%)
MSFT  485.50
+8.51 (1.78%)
NVDA  180.26
+2.44 (1.37%)
ORCL  204.96
+7.93 (4.02%)
TSLA  426.58
+7.18 (1.71%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.